MLYS | Mineralys Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	14.06 - 15.68
52 Week Range	8.24 - 18.38
Beta	2.14
Implied Volatility	399.28%
IV Rank	11.41%
Day's Volume	542,471
Average Volume	897,400
Shares Outstanding	62,784,878
Market Cap	966,259,272
Sector	Healthcare
Industry	Biotechnology
IPO Date	2023-02-10

Valuation
Profitability
Growth
Health
P/E Ratio	-4.20
Forward P/E Ratio	N/A
EPS	-3.66
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	28
Country	USA
Website	MLYS

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

MLYS's peers: ACXP, ADAG, ANTX, ALXO, ANEB, ANIX, APLT, APRE, ATXS, AVTE, AVTX, BCDA, BCYC, PMCB, CADL, CCCC, CDXS, CELC, CGEM, CLNN, CNTA, CORT, DYN, ENTA, ERAS, EWTX, FDMT, FHTX, FOLD, GHRS, GLYC, GNTA, IGMS, IMNM, IMTX, INBX, IPSC, IVA, JANX, KROS, KYMR, KZR, LYEL, MDWD, MDXG, MGNX, MNPR, MOLN, MRUS, NKTX, OLMA, ORIC, PHAR, PHVS, PMVP, PRAX, PRLD, PRTC, RAPT, REPL, RLAY, RLYB, RNA, SEER, ACRV, SLDB, SLGL, SLN, SNDX, SRRK, STRO, TNGX, TYRA, VALN, VERA, XLO, XNCR, BLTE, HLVX, PEPG, SNTI, QNCX, NAMS, IRON, MLEC, CVKD

*Chart delayed

Analyzing fundamentals for MLYS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see MLYS Fundamentals page.

Watching at MLYS technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on MLYS Technicals page.